MACROGENICS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
9704 MEDICAL CENTER DRIVE, Rockville, MD, 20850
Mailing Address
9704 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Phone
301-251-5172
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$201.25M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 10-K Annual financial report | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
Annual Reports
10-K
March 9, 2026
- Margetuximab achieved market share expansion and positive real-world data, bolstering its commercial trajectory.
- Lorigerlimab successfully advanced to Phase 2b for solid tumors, with initial data expected in Q4 2026.
Material Events
8-K
Other
February 24, 2026
High Impact
- Lorigerlimab targets platinum-resistant ovarian cancer, a challenging gynecologic cancer with limited treatment options.
- The market for platinum-resistant ovarian cancer is estimated to be worth billions.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.